
|Articles|July 1, 1999
Supplements and Featured Publications
- Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
- Volume 5
- Issue 10 Suppl
Bibliography
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Assessment of Quality-of-Life Outcomes in Schizophrenic Patientsover 26 years ago
The Emerging Role of Psychiatric Pharmacistsover 26 years ago
CME/CE Quizover 26 years ago
Selected AbstractsNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
5














































